Cellectar Biosciences, Inc.
Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer

Last updated:

Abstract:

Disclosed herein is a fractionated dosing regimen of .sup.131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer.

Status:
Application
Type:

Utility

Filling date:

10 Apr 2019

Issue date:

15 Apr 2021